The net worth of several pharmaceutical securities investment funds rose

[Pharmaceutical Network Pharmaceutical Stock Market] On March 23, the net value of a number of pharmaceutical securities investment funds rose, including Huatai Pineapple Biomedical Mixed C, Southern Pharmaceutical Innovation Stock A, E Fund Biomedical Biostock A, Fuguo Biomedical Technology Mixed C, Galaxy Medicine Mixed, Cinda Australia Silver Medicine and Health Mix,
etc.

The net value of Huatai-Pineapple Biopharmaceutical Mixed C rose 3.
24% On March 23, the new net value of Huatai-Bairui Biomedical Mixed C rose 3.
24%
.

The securities investment fund has returned -7.
61% since its establishment on August 20, 2020, -17.
51% since 2022, 1.
07% in the past month, and -4.
09% in the past year
.

According to the report, the fund’s heavily held stocks include WuXi AppTec, Asymchem, Pro Pharma, Porton, Mindray Medical, Tofflon, Yixintang, Aier Eye, Opcon Vision, Pien Tze Huang, etc.
Among them, WuXi AppTec Positions accounted for 9.
45%
.

The net value of Nanfang Pharmaceutical Innovation Stock A rose 3.
24% According to the March 23 information released by Nanfang Pharmaceutical Innovation Stock A, the new net value rose 3.
24%
.

The securities investment fund was established on March 2, 2021, with a return of -37.
57% since its establishment, -17.
76% this year, -0.
46% in the past month, and -37.
56% in the past year
.

 　　Periodic reports show that the fund's heavily held stocks include Yaoshi Technology, Tigermed, WuXi AppTec, Asymchem, GenScript Biotechnology, Mindray Medical, Wantai Bio, Aibo Medical, Zhaoyan New Drug, Huitai Medical,
etc.

 　　The net value of E Fund Biotech stock A rose by 3.
15%.
The new net value of E Fund Biotech stock A on March 23 rose by 3.
15%
.

The fund has accumulated income of -38.
68% since its establishment on November 4, 2020, -21.
81% this year, -2.
36% in the past month, and -34.
43% in the past year
.

 　　Periodic reports show that the fund's heavily held stocks include WuXi AppTec, Aier Ophthalmology, Changchun High-tech, Rongchang Bio-B, WuXi Biologics, Innovent Bio, Hengrui Medicine, Nanwei Medicine, Jinyu Medical, GenScript Biotechnology etc.

_
 　　Wells Fargo Biomedical Technology Mixed C net worth rose 3.
06% Wells Fargo Biomedical Technology Mixed C announced its new net worth on March 23, up 3.
06%
.

Fuguo Biomedical Technology Hybrid C was established on January 18, 2021, with a profit of -18.
33% since its establishment, -16.
55% this year, 1.
69% in the past month, and -12.
21% in the past year
.

 　　Periodic reports show that the fund's heavily held stocks include WuXi AppTec, Pharmaron, Mindray Medical, Pumen Technology, Aier Eye, Asymchem, Sunshine Novo, Zhifei Bio, Medicil, and Huitai Medical
.

 　　Galaxy Pharma Hybrid net worth rose 4.
15% Galaxy Pharma Hybrid's new net worth on March 23 rose 4.
15%
.

Galaxy Pharma was established on June 17, 2021.
The fund has gained -30.
78% since its establishment, -16.
29% this year, and 0.
84% ​​in the past month
.

 　　Periodic reports show that the fund's heavily held stocks include Asymchem, Tigermed, Yaoshi Technology, Golden Mile Medical, Mindray Medical, CTI Testing, WuXi AppTec, Zhaoyan New Drug, Tongce Medical, and Wuwu Biotechnology
.

 　　The net worth of Cinda Australia Silver Medicine and Health Mixed Up 3.
16% The new net worth of Cinda Australia Silver Medicine and Health Mixed rose 3.
16% on March 23
.

The fund was established on April 9, 2021, with a return of -18.
02% since its establishment, a return of -16.
22% this year, and a return of 0.
55% in the past month
.

 　　Periodic reports show that the fund's heavily held stocks include Medicilon, Zhaoyan New Drug, WuXi AppTec, Mindray Medical, Tigermed, Pharmaron, Wantai Bio, OPTV, Haitai Xinguang, Amic,
etc.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.